Loading...

Aptinyx

Nasdaq:APTX
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
APTX
Nasdaq
$99M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • Aptinyx has significant price volatility in the past 3 months.
APTX Share Price and Events
7 Day Returns
-2.3%
NasdaqGS:APTX
-0.6%
US Biotechs
0.5%
US Market
1 Year Returns
-
NasdaqGS:APTX
-8.8%
US Biotechs
0.8%
US Market
APTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aptinyx (APTX) -2.3% -16% -29.8% - - -
US Biotechs -0.6% -0.9% -9.1% -8.8% 11.6% 4.7%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • No trading data on APTX.
  • No trading data on APTX.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

APTX Value

 Is Aptinyx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aptinyx. This is due to cash flow or dividend data being unavailable. The share price is $2.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aptinyx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aptinyx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:APTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.14
NasdaqGS:APTX Share Price ** NasdaqGS (2019-06-14) in USD $2.95
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aptinyx.

NasdaqGS:APTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:APTX Share Price ÷ EPS (both in USD)

= 2.95 ÷ -2.14

-1.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptinyx is loss making, we can't compare its value to the US Biotechs industry average.
  • Aptinyx is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aptinyx's expected growth come at a high price?
Raw Data
NasdaqGS:APTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-18.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aptinyx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aptinyx's assets?
Raw Data
NasdaqGS:APTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.03
NasdaqGS:APTX Share Price * NasdaqGS (2019-06-14) in USD $2.95
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:APTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:APTX Share Price ÷ Book Value per Share (both in USD)

= 2.95 ÷ 4.03

0.73x

* Primary Listing of Aptinyx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptinyx is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Aptinyx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aptinyx has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

APTX Future Performance

 How is Aptinyx expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aptinyx expected to grow at an attractive rate?
  • Unable to compare Aptinyx's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aptinyx's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Aptinyx's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:APTX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:APTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -18.2%
NasdaqGS:APTX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 5.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:APTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:APTX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 5 -107 -144 3
2022-12-31 5 -96 -142 2
2021-12-31 5 -90 -150 2
2020-12-31 4 -76 -93 5
2019-12-31 4 -66 -79 5
NasdaqGS:APTX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 5 -52 -58
2018-12-31 7 -47 -53
2018-09-30 7 -41 -46
2018-06-30 7 -37 -40
2018-03-31 6 -35 -35
2017-12-31 5 -33 -32
2016-12-31 10 -20 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aptinyx is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Aptinyx's revenue is expected to grow by 5.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:APTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Aptinyx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:APTX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.43 -2.43 -2.43 1.00
2022-12-31 -2.42 -2.42 -2.42 1.00
2021-12-31 -2.94 -2.94 -2.94 1.00
2020-12-31 -2.25 -1.79 -2.77 4.00
2019-12-31 -2.24 -2.09 -2.50 4.00
NasdaqGS:APTX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.14
2018-12-31 -2.64
2018-09-30 -3.52
2018-06-30 -6.96
2018-03-31 -6.65
2017-12-31 -6.17
2016-12-31 -3.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aptinyx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aptinyx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aptinyx has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

APTX Past Performance

  How has Aptinyx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aptinyx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aptinyx does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Aptinyx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aptinyx's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aptinyx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aptinyx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:APTX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 5.00 -58.32 16.35
2018-12-31 6.57 -53.28 12.67
2018-09-30 6.72 -46.41 9.59
2018-06-30 6.98 -40.38 7.12
2018-03-31 6.28 -35.04 6.37
2017-12-31 4.96 -32.07 5.55
2016-12-31 9.79 -15.48 4.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aptinyx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aptinyx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aptinyx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aptinyx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aptinyx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

APTX Health

 How is Aptinyx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aptinyx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aptinyx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aptinyx's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aptinyx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aptinyx has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aptinyx Company Filings, last reported 2 months ago.

NasdaqGS:APTX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 134.69 0.00 136.58
2018-12-31 149.31 0.00 150.64
2018-09-30 161.97 0.00 165.58
2018-06-30 175.54 0.00 179.09
2018-03-31 81.52 0.00 82.35
2017-12-31 92.67 0.00 92.14
2016-12-31 14.10 0.00 16.18
  • Aptinyx has no debt.
  • Aptinyx has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aptinyx has sufficient cash runway for 2.6 years based on current free cash flow.
  • Aptinyx has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 35.8% each year.
X
Financial health checks
We assess Aptinyx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aptinyx has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

APTX Dividends

 What is Aptinyx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aptinyx dividends.
If you bought $2,000 of Aptinyx shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aptinyx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aptinyx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:APTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:APTX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aptinyx has not reported any payouts.
  • Unable to verify if Aptinyx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aptinyx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aptinyx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aptinyx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aptinyx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aptinyx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

APTX Management

 What is the CEO of Aptinyx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Norbert Riedel
COMPENSATION $10,605,446
AGE 60
TENURE AS CEO 4 years
CEO Bio

Dr. Norbert G. Riedel, Ph.D., serves as Board Member at TRACT Therapeutics, Inc. He serves as Chairman of Eton Pharmaceuticals, Inc. and serves as Industry Advisor at Agent Capital, LLC. He has been President, Chief Executive Officer and Director of Aptinyx Inc. since June 2015. He serves as a Senior Executive Advisor at Beecken Petty O'Keefe & Company. Dr. Riedel served as the Chief Executive Officer and President of Naurex, Inc. since January 1, 2014 to September 2015. Dr. Riedel served as the Chief Science & Innovation Officer and Corporate Vice President of Baxter International Inc., from May 2001 to 2013. He served as Senior Vice President of Baxter International Inc. From 1998 to March 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit of Baxter International Inc. He served as General Manager of the recombinant therapeutic proteins business at Baxter. Prior to joining Baxter in 1998, he served as the Head of worldwide/Global Biotechnology and Global Core Research Functions at Hoechst Marion Roussel Inc. (now Sanofi-Aventis) from 1996 to 1998. He served as the Chairman of the Board of Biotechnology Industry Organization since July 1, 2006. He served as Deputy Chairman of Supervisory Board at MediGene AG., until July 16, 2013. He has been an Independent Director of Jazz Pharmaceuticals Public Limited Company since May 2, 2013. He serves as a Member at Large of Illinois Biotechnology Industry Organization. He served as a Director of DuPont Industrial Biosciences (Danisco US Inc.) since November 2000. He has been a Director of Naurex, Inc since December 2012. He has been Director of Eton Pharmaceuticals, Inc. since September 7, 2017. He serves as a Director of Nanomateria Inc., Biotechnology Innovation Organization and iBIO Institute. He serves as a Member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology. Dr. Riedel is a member of the Austrian Academy of Sciences and Illinois Innovation Council. He served as a Member of Scientific Advisory Board of GlycoFi, Inc. He served as a Director of Ariad Pharmaceuticals, Inc. from April 28, 2011 to February 16, 2017. He served as a Member of the Supervisory Board at MediGene AG since October 27, 2003. He served as an Independent Director of Oscient Pharmaceuticals Corp. (formerly, Genome Therapeutics Corp.) since 1999. He served as an Assistant Professor and Associate Professor of Medicine and Biochemistry at Boston University School of Medicine from 1987 to 1991 and a Visiting Professor at Massachusetts Institute of Technology since 1992. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University’s Feinberg School of Medicine. He has a Diploma in Biochemistry from the University of Frankfurt in 1981. Dr. Riedel received his Ph.D. in Biochemistry from the University of Frankfurt in 1983. He was a Postdoctoral Fellow at Harvard University from 1984 to 1987.

CEO Compensation
  • Norbert's compensation has increased whilst company is loss making.
  • Norbert's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Aptinyx management team in years:

0.5
Average Tenure
49
Average Age
  • The average tenure for the Aptinyx management team is less than 2 years, this suggests a new team.
Management Team

Norbert Riedel

TITLE
President
COMPENSATION
$11M
AGE
60
TENURE
4 yrs

Ashish Khanna

TITLE
CFO & Chief Business Officer
COMPENSATION
$2M
AGE
42
TENURE
1.3 yrs

Andy Kidd

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
42
TENURE
0.3 yrs

Juan Estupinan

TITLE
Vice President of Finance & Accounting and Controller
TENURE
0.3 yrs

Joseph Moskal

TITLE
Chief Scientific Officer
COMPENSATION
$498K
AGE
67
TENURE
3.9 yrs

Patricia Adams

TITLE
Vice President of Human Resources & Administration
TENURE
0.3 yrs

Betty Jang

TITLE
Vice President of Legal Affairs
AGE
49
TENURE
0.5 yrs

Nick Smith

TITLE
Director of Corporate Development

Kathryn King

TITLE
Senior Vice President - Clinical Development
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Aptinyx board of directors in years:

3.1
Average Tenure
56.5
Average Age
  • The tenure for the Aptinyx board of directors is about average.
Board of Directors

Bill Gantz

TITLE
Chairman of the Board
COMPENSATION
$38K
AGE
80

Norbert Riedel

TITLE
President
COMPENSATION
$11M
AGE
60
TENURE
4 yrs

Jamie Topper

TITLE
Director
COMPENSATION
$23K
AGE
56
TENURE
3.1 yrs

Adam Koppel

TITLE
Director
COMPENSATION
$24K
AGE
48
TENURE
1.5 yrs

Bob Hombach

TITLE
Director
COMPENSATION
$218K
AGE
52
TENURE
1.1 yrs

Patrick Enright

TITLE
Director
COMPENSATION
$24K
AGE
57
TENURE
3.1 yrs

Terry Gould

TITLE
Director
COMPENSATION
$21K
AGE
61
TENURE
3.9 yrs

Henry Gosebruch

TITLE
Director
AGE
45
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Aptinyx insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
09. May 19 Buy Henry Gosebruch Individual 07. May 19 08. May 19 100,000 $3.86 $385,624
30. Jan 19 Buy Torsten Madsen Individual 28. Jan 19 28. Jan 19 1,050 $5.27 $5,534
28. Jan 19 Buy Robert Hombach Individual 24. Jan 19 25. Jan 19 25,000 $5.54 $138,233
19. Jan 19 Buy Ashish Khanna Individual 18. Jan 19 18. Jan 19 10,000 $5.45 $54,500
26. Jun 18 Buy Bain Capital, LP Company 25. Jun 18 25. Jun 18 400,000 $16.00 $6,400,000
26. Jun 18 Buy Frazier Healthcare Partners Company 25. Jun 18 25. Jun 18 150,000 $16.00 $2,400,000
26. Jun 18 Buy New Leaf Venture Partners, L.L.C. Company 25. Jun 18 25. Jun 18 250,000 $16.00 $4,000,000
26. Jun 18 Buy Adams Street Partners, LLC Company 25. Jun 18 25. Jun 18 150,000 $16.00 $2,400,000
26. Jun 18 Buy Longitude Capital Management Co., LLC Company 25. Jun 18 25. Jun 18 150,000 $16.00 $2,400,000
26. Jun 18 Buy Wilbur Gantz Individual 25. Jun 18 25. Jun 18 23,100 $16.00 $369,600
26. Jun 18 Buy Joseph Moskal Individual 25. Jun 18 25. Jun 18 3,000 $16.00 $48,000
26. Jun 18 Buy Torsten Madsen Individual 25. Jun 18 25. Jun 18 1,000 $16.00 $16,000
26. Jun 18 Buy Andrew Kidd Individual 25. Jun 18 25. Jun 18 6,700 $16.00 $107,200
26. Jun 18 Buy Ashish Khanna Individual 25. Jun 18 25. Jun 18 7,800 $16.00 $124,800
26. Jun 18 Buy Norbert Riedel Individual 25. Jun 18 25. Jun 18 2,400 $16.00 $38,400
26. Jun 18 Buy Robert Hombach Individual 25. Jun 18 25. Jun 18 24,100 $16.00 $385,600
X
Management checks
We assess Aptinyx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aptinyx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

APTX News

Simply Wall St News

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Aptinyx Inc. … Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. … In the last twelve months Aptinyx insiders were buying shares, but not selling

Simply Wall St -

How Many Insiders Bought Aptinyx Inc. (NASDAQ:APTX) Shares?

Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … (NASDAQ:APTX), you may well want to know whether insiders have been buying or selling. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'.

Simply Wall St -

Do Insiders Own Lots Of Shares In Aptinyx Inc. (NASDAQ:APTX)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of US$678m, Aptinyx is a small cap stock, so it might not be well known by many institutional investors. … We can zoom in on the different ownership groups, to learn more about APTX

Simply Wall St -

Are Aptinyx Inc's (NASDAQ:APTX) Interest Costs Too High?

The direct benefit for Aptinyx Inc (NASDAQ:APTX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is APTX will have to adhere to stricter debt covenants and have less financial flexibility. … Is APTX right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

How Financially Strong Is Aptinyx Inc (NASDAQ:APTX)?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does APTX's growth rate justify its decision for financial flexibility over lower cost of capital … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt.

Simply Wall St -

APTX Company Info

Description

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Details
Name: Aptinyx Inc.
APTX
Exchange: NasdaqGS
Founded: 2015
$99,008,522
33,562,211
Website: http://www.aptinyx.com
Address: Aptinyx Inc.
909 Davis Street,
Suite 600,
Evanston,
Illinois, 60201,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS APTX Common Stock Nasdaq Global Select US USD 21. Jun 2018
NasdaqGS APTX COM Nasdaq Global Select US USD 16. Jun 2019
Number of employees
Current staff
Staff numbers
63
Aptinyx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 01:02
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/05/28
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.